

## DAFTAR PUSTAKA

- Agarwal KS.2014. Integrin and cadherin as therapeutic targets in fibrosis. *Front Pharmacol*.5: 131.
- Ahtikoski AM, Koskinen SO, Virtanen P, Kovanen V, Risteli J, Takala TE. 2003. Synthesis and degradation of type IV collagen in rat skeletal muscle during immobilization in shortened and lengthened positions. *ActaPhysiolScand*; 177:473-81.
- Alexander JS, Elrod JW. 2002. Extracellular matrix, junctional integrity and matrix metalloproteinaseinteractions in endothelial permeability regulation. *J Anat*. 200(6):561–74.
- Al-Singary W, Arya M, Patel HR. 2004. Bladder neck stenosis after transurethral resection of prostate : does size matter?. *Urol Int*.73: 262-5.
- Amaleinei C, Irina DrogaCarutu, RalucaAnca Balan.2007. Biology of Metalloproteases and remodelin. *Rom J Morphol Embryol*. 48(4):323-34.
- Arakaki PA, Marques MR, Santos MCLG.2009. MMP-1 polimorphism and its relationships to pathological processes. *J Biosci*.34(2):313-20.
- AUA Practice guidelines committee.2003. AUA guide lines on management of benign prostate hyperplasia. Chapter 1: diagnosis and treatment recommendation. *J Urol*. 170:530-47.
- Baker AH, Edwards DR, Murphy G. 2002. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. *J Cell Sci*.115:3719-27.
- Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-canicM . 2008. Growth factors and cytokines in wound healing. *Wound repair regen*.16: 585.
- Bellayr IH, Walter TJ, Li Y.2010. Scarless wound healing. *J Am Coll Clin Wound Spec*. 2: 40-3.
- Berman DM, Rodriguez R. 2012. Development, Molecular ,Biology, and Physiologyof the Prostate. In: Wein A.J,Kavoussu L.R,Novick N.C,Partin .A.W, Peters C.A , Editors.Campbell-Walsh Urology . 10<sup>th</sup> ed.Philadelphia : Saunders Elsevier; P. 2519-54.
- Blomme EA, Chinn KS, Hardy MM, Casler JJ, Kim SH, Opsahl AC,*et al*. 2003. Selective cyclooxygenase – 2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. *Br.J. Dermatol*. 148: 211-23.

- Bobadila M, Sainz N, Rodriguez JA, Abizanda G, Orbe J, deMartino A, *et al.* 2014. MMP-10 is required for efficient muscle regeneration in mouse models of injury and muscular dystrophy. *Stem cells.* 32:447-61.
- Borboroglu PG, Sands JP, Roberts JL, Amling CL. 2000. Risk factors for vesico urethral anastomotic stricture after radical prostatectomy. *Urology.* 56:96-100.
- Bradshaw AD, Reed MJ, Sage EA. 2002. SPARC-null mice exhibit accelerated cutaneous wound closure. *J HistochemCytochem .* 50: 1-10.
- Brew K, Dinakarbandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. *Biochim.Biophys.Acta;* 1477(1-2):267-83.
- Brenneisen P, Wenk J, Wlaschek M, Krieg T, Scharffetter-Kochanek K. 2000. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. *J Biol Chem.* 275:4336-44.
- Caine M. 1986. The present Role of alpha -adrenergic blocker in treatment of benign prostatic hypertrophy. *J Urol.* 136:1-4.
- Chen C. 2001. The Angiogenic factor Cyr61 activates a genetic program for wound in human skin fibroblasts. *J Biol Chem.* 276: 4732-37.
- Cheon H, YU SJ, Yoo DH, Chae IJ, Song GG, Shon J. 2002. Increased expression of Pro Inflammatory cytokines and metalloproteinase-1 By TGF-B1 in Synovial fibroblasts from rheumatoid arthritis and normal individuals. *Clin Exp Immunol.* 127:547-52.
- Chungtai B, Lee R, Te A, Kaplan S. 2011. Role of inflammation in benign prostatic hyperplasia. *Reviews in urology.* 13(3) 147-50.
- Claus G, Roehrborn. 2011. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia ( BPH). *Med Clin N Am.* 95: 87-100.
- Claus G. Roehrborn. 2012. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. In: Wein A.J, Kavoussi L.R, Novick N.C, Partin .A.W, Peters C.A , Editors. *Campbell-Walsh Urology .* 10<sup>th</sup> ed. Philadelphia : Saunders Elsevier; P. 2556-97.
- Cox TR, Erler JT. 2011. Remodeling and homeostasis of the extracellular matrix: Implication for fibrotic disease and cancer. *Disease Models and mechanism.* 4:165-78.

- Colon I, Payne RE. 2008. Benign prostate Hyperplasia and lower Urinary tract Symptoms in African American and Latinos: Treatment in the Context of common Comorbidities. *J.amfmed.*121:18-26.
- Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M. 2014. Benign prostate hyperplasia: A New MetabaolicDesease of the Aging Male and Its Corelation with sexual Dysfunction. Review. *Int J Endocrinol.* 2014: 1-14.
- CornuJN, Cussenot O, Haab F, Lukack B. 2010. Re: A Widespread Population Study of Actual Medical Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia Across Europe and Beyond Official Clinical Guidelines. *Eur Urol.* 58: 450-6.
- Cunha GR. 2004. Role of stromal–epithelial interactions in hormonal response. *Arc Cytol.*67:417-34.
- Denton CP, Abraham DJ. 2001. Transforming growth factor beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. *Curr Opin Rheumatol.*13: 505-11.
- Denton CP, Khan K, Hoyles RK, Shiwen X, Leoni P, Chen Y, Eastwood M, Abraham DJ, 2009. Inducible lineage specific deletion of T betaRII in fibroblas deines a pivotal regulatory role during adult skin wound healing. *J Invest Dermato.*129:194
- DiSilviaraF, Gentile V, DeMatteis A, Gianna M, VoriaG,Pastore L, *et al.* 2003. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. *Eur Urol.* 43:164-175.
- [Distler JH](#), [Schett G](#), [Gay S](#), [Distler O](#).2008. The controversial role of tumor necrosis factor alpha in fibrotic disease. *Arthritis Rheum.* 58: 2228-35.
- [Doluoglu OG](#), [Gokkaya CS](#), [Aktas BK](#), [Oztekin CV](#), [Bulut S](#), [Memis A](#),*et al.* 2012. Impact of asymptomatic prostatitis on re-operation due to urethral stricture of bladder neck contracture developed after TUR-P. *Int Urol Nephro.* 44: 1085-90.
- Dunsmore SE, Saarialho-Kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, *et al.* 1998. Matrilysinexpression and function in airway epithelium. *J ClinInvest.*102(7):1321–31.
- Eddy AA. 2011. Overview of celluler and molecular basis of kidney fibrosis. *Kidney Int Suppl.* 4: 2-8.
- Elshal AM, Elkoushy MA, El-Nahas AR, Shoma AM, Nabeeh A, Carrier S, *et al.* 2015. GreenLight™ laser (XPS) photoselective vapo-enucleation versus holmium laser enucleation of the prostate for the treatment of symptomatic benign prostate hyperplasia: a randomized controlled study. *J Urol.* 193(3):927-34.

- Elterman D, Kaplan SA. 2014. Lower urinary tract symptoms in a 66 – year – old man. *CMAJ*, 186:525-27.
- Fallowfield JA, [Mizuno M](#), [Kendall TJ](#), [Constandinou CM](#), [Benyon RC](#), [Duffield JS](#), *et al.* 2007. Scar associated macrophages are a major source of hepatic matrix metalloproteinases-13 and facilitate the resolution of murine hepatic fibrosis. *J Immunol*.178: 5288-95.
- Fathke C, Wilson L, Shah K, Kim B, Hocking A, Moon R, *et al.* 2006. Wnt signalling induces epithelial differentiation during cutaneous wound healing. *BMC Cell Biol* ;7:1017-26.
- Finnsen KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, Bizet AA, Philip A. 2006. Identification of CD109 as part of the TGF  $\beta$  receptor system in human keratinocytes. *FASEB*.20: 1525.
- Fiuk J, Nuss G R, Gonzalez CM.2012. Risk factors for urethral stricture and bladder neck contracture following transurethral prostatectomy for BPH/LUTS. *J Urol*. 187: 1.
- Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. 2013. Proteinases and Matrix Degradation. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR. Kelley's. Textbook of rheumatology. Ed9<sup>th</sup> . Saunders. 97-115
- Frangogiannis NG.2017. The role of transforming growth factor (TGF)- $\beta$  in the infarcted myocardium. *J Thorac* .9 (Suppl): S52-S63
- Freedber IM, Tomic-Canic M, Komine M, Blumenberg M. 2002. Keratins and the keratinocyte activation cycle. *J Invest Dermatol* .116: 633-40.
- Fritzpatrick JM, Desgrandchamps F, Adjali K, Guerra LG, Hong SJ, Khleid SE, *et al.* 2011. Management of acute urinary retention : a worldwide survey of 6074 men with benign prostatic hyperplasia. *BJU Int*.109:88-95.
- Foster HE, [Jacobs M](#), [D'Alema A](#). 2004. Transurethral Resection of the Prostate. In: McVary KT, Editor. Management of Benign Prostatic. New Jersey: Humana Press. P:174-205
- Gao B , Radaeva S, Jeong W. 2007. Activation of natural killer cells inhibits liver fibrosis: a Novel strategy to treat liver fibrosis. *Expert Rev Gastroenterol Hepatol*. 1: 173-80.
- Garrison J Band Kyprianou N.2006. Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a Death Receptor–Mediated Pathway. *Cancer Res* . 66: 464-72.
- Gawronska–Kozak B, Bogacki M, Rim JS, Monroe WT, Manuel JA. 2006. Scarless skin repair in immunodeficient mice. *Wound repair regen*. 14: 265-76.

George NJR.2010. The Prostate. In: Brocklehurst's textbook of geriatric medicine and gerontology.701-15.

Gill SE, Parks W.2008. Metalloproteinases and Their Inhibitors: Regulators of WoundHealing.*Int J Biochem Cell Biol.* 40(6-7): 1334-47

Haas A. 1995. Wound healing. *DermatolNurs.* 7: 28-34.

Hantash BM, Zhao L, Knowles JA, Lorenz HP. 2008. Adult and fetal wound healing. *From Biosic.* 13: 51-61.

Harkawai RC, Issa MM. 2006. Medical and minimally invasive therapies for treatment of benign prostatic hyperplasia. *Prostatate Cancer Prostatic Dis.*9:204-214.

Hay N, Sonenberg N. 2004. Upstream and downstream of mTOR. *Genes and development* .18:1926-45.

Hoffmann R.2005. Transurethrale Resektion (TURP) und transurethrale Inzision (TUIP) der Prostata. In: Hoffmann R, editor. *Endoskopische Urologie.* Heidelberg: Springer;. p. 50-84.

Huang X, Wang L, Wang XH, Shi HB, Zhang XJ, Yu ZY. 2012. Bipolar Transurethral Resection of the prostate causes deeper coagulation and less Bleeding Than Monopolar Transurethral Prostatectomy. *Urology* 80:1116-20.

Inoue M, Kratz G, Haegerstrand A, Stähle-Bäckdahl M. 1995. Collagenase expression is rapidly induced in wound-edge keratinocytes after acute injury in human skin, persists during healing, and stops at reepithelialization. *J. Invest. Dermatol.* 104:479-83.

Izumi K, Mizokami A, Lin AJ, Lai KP, Chang C. 2013. Androgen receptor roles in the development of benign prostate hyperplasia. *Am J Pathol*, 182: 1942-9.

IAUI, 2000. Pedoman pentalaksanaan BPH di Indonesia. IAUI guide lines, pp 1-19.

Ji X, Wang L, Wu B, Han R, Han L, Wang T, *et al.* 2015. Association of MMP-1, MMP2 and MMP3 genes polymorphism with coal workers pneumoconiosis in Chinese han population. *Int J Environ Res.* 12:13901-12.

Kaplan SA, Neutel J. 2006. Vasodilatory factors in treatment of elder men with symptomatic benign prostatic hyperplasia. *Urology.*67:225-31.

Kapitein B, Tiemessen MM, Liu WM, Dijk VI, Hoekstra MO, Hoffen EV, *et al.* 2006. The Interleukin-10 inducing effect of transforming growth factor-B on human naïve CD 4 T cells from cord blood is restricted to the Th1 subset. *J Clin Exp Immunol.*147:352-8.

- Kaufman J [Sime PJ](#), [Phipps RP](#). 2004. Expression of CD154 (CD 40 ligand) by human lung fibroblasts: Differential regulation by IFN-gamma and IL-13 and implication for fibrosis. *J. Immunol.*172: 1862-71.
- Keil KP, Abler LL, Laporte J, Altman HM, Yang B, Jarrard DF, Hernandez LL, *et al.* 2014. Androgen receptor DNA methylation regulates the timing and androgen sensitivity of mouse prostate ductal development. *Dev Biol.* 396 (2): 237-45.
- Kellerman, Rick D. 2015. *Conn's Current Therapy 2015*. Saunders Goldman L, Schafer A I. Benign Prostate Hyperplasia and Prostatitis. In: Goldman's Cecil Medicine. 24<sup>th</sup> Ed. Saunders 2012. 805-10.
- Kermani MG, Macoska JA. 2013. Promising Molecular Targets and Biomarkers for Male BPH and LUTS. *CurrUrol Rep.* 14 (6): 1-17.
- Kim I, Mogford JE, Witschi C, Nafissi M, Mustoe TA. 2003. Inhibition of prolyl 4-hydroxylase reduces scar hypertrophy in a rabbit model of cutaneous scarring. *Wound Repair Regen*;11 368-72.
- Krizkova S.2011.Clinical importance of matrix metalloproteases. *BratislLekLesty* 122(8):435-40.
- [Kurasawa K](#), [Hirose K](#), [Sano H](#), [Endo H](#), [Shinkai H](#), [Nawata Y](#), *et al.* 2000. Increased interleukin-17 production in patients with systemic sclerosis. *Arthritis Rheum*, 43: 2455-63.
- Kurtz A, Aigner A, Cabal-Manzano R, Butler R, Hood D, Sessions R, *et al.* 2004. Differential regulation of a fibroblast growth factor binding protein during skin carcinogenesis and wound healing. *Neoplasia.* 6:595-602.
- Kumar VL, Wahane VD.2008. Current Status of 5 $\alpha$ -Reductase Inhibitors in The Treatment of Benign Hyperplasia of Prostat. *India J Med Sci.*62.
- Kwon OJ, Xin L. 2014. Prostate stem and progenitor cells. *Am J Clin Exp Urol.*2(3):209-18.
- Lan HY. 2011. Diverse roles of TGF- $\beta$ /Smads in renal fibrosis and inflammation. *Int.J.Biol.*7(7):1056-67.
- Larjava H, Wiebe C, Behm CG, Hart DA, Heino J, Hakkinen L. 2011. Exploring scarless healing of oral soft tissue. *J Can Dent Assoc.* 77: 18-23.
- Lauer-Fields JL, Juska D, Fields GB. 2002. Matrix metalloproteinases and collagen catabolism. *Biopolymers.* PMID:12228918; <http://dx.doi.org/10.1002/bip.10201>. 66:19-32;
- Lee YH, Chiu AW, Huang JK. 2005. Comprehensive study of bladder neck contracture after transurethral resection of prostate. *Urology.* 65: 498-503.

- [Lenga Y, Koh A, Perera AS, McCulloch CA, Sodek J, Zohar R.2008.](#)  
Osteopontin expression is required for myofibroblasts differentiation. *Circ. Res.*102: 319-27.
- Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N. 2005. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5  $\alpha$ -reductase inhibitors dutasterid :result of 4 years studies. *BJU Int.* 96:572-77.
- Macedo L, Pinhal-Enfield G, Alshits V, Elson G. 2007. Wound Healing is impaired in MyD88-deficient mice: a role for MyD88 in the regulation of wound healing by adenosine A2A receptors. *Am J Pathol.* 171:1774-87.
- Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH. 2004. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). *EurUrol.* 46:547-54.
- Mahakalkar CC, Prasad A, Kaple MN, Jain NN, Khadatkar AR, Jaipuriya PK. 2016. Predictors of urinary retention in benign prostatic hyperplasia. *Int J Res Med Sci.* 4 (2):486-90.
- Mannan R, Misra V, Misra SP, Singh PA, Dwivedi M. 2014. A Comparative evaluation of scoring system for assessing necro inflammatory activity and fibrosis in liver biopsies of patients with chronic viral hepatitis. *J Clin Diagn Res.*8(8):8-12.
- Marszalek M, Ponholzer A, Pusman M, Berger I. 2009. Transurethral Resection of the Prostate. *European Urology Supplement.*8:504-12.
- Matthew Giannandrea and William C. Parks. 2014. Diverse functions of matrix metalloproteinases during fibrosis. *Disease Models and Mechanisms.* 7;193-203.
- May F, Hartung R. 2006. Surgical Atlas Transurethral resection of The Prostate. *BJU International.*98:921-34.
- McLaren ID, Jerde TJ, Bushman W. 2011. Role of interleukins , IGF and Stem cells in BPH. *Differentiation.* 82: 1-14.
- McCawley LJ, O'Brien P, Hudson LG. 1998. Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)- mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. *J. Cell Physiol.* 176(2):255-265.
- McGuire JK, Li Q, Parks WC. 2003. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. *Am J Pathol.* 162(6):1831-43.

- [Moldoveanu C](#), [Geavlete B](#), [Stănescu F](#), [Jecu M](#), [Adou L](#), [Bulai C](#), *et al.* 2013. Tips and Tricks in Secondary Bladder neck sclerosis bipolar plasma vaporization approach. *J Med Life*. 6: 272-77.
- Muller M, Trocme C, Lardy B, Morel F, Halimi S, Benhamou P. 2008. Matrix metalloproteinases and diabetic foot ulcers: the ratio of MMP-1 to TIMP-1 is a predictor of wound healing. *Diabet* . 25:419-26.
- Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, *et al.* 1999. The integrin alpha v beta 6 binds and activates latent TGF  $\beta$  1: a mechanism for regulating pulmonary inflammation and fibrosis. 96:319.
- Murashima A, Kishigami S, Thomson A, Yamada G. 2015. Androgens and mammalian malereproductive tract development. *Biochemical et Biophysical Acta*.1849: 163-70.
- Naber KG, Weidner W. 2000. Chronic prostatitis-an infectious disease?. *J AntimicrobChemother.*; 46:157-161.
- Nagase H, VisseR, Murphy G. 2006. Structure and function of Matrix metalloproteinases and TIMPs. *Cardiovascular Research*.69:562-73.
- Narayan P, O'Leary MP, Davidai G. 2005. Early efficacy of tamsulosin versus terazosin in treatment of men with benign prostatic hyperplasia: a randomized, open label trial. *J Appl Res*.5:237-45.
- NautaA, Larson B, Longakaer MT, Lorens PiH. 2011. Scarless wound healing In: Atala A, Thomson J A, Derem R, Lanza R. Editors. *Principles of Regenerative Medicine 2<sup>nd</sup> ed.* Philadelphia : Sounders Elsevier P. 103-27.
- Nicholson T M , Ricke WA. 2011. Androgen and estrogen in benign prostatic hyperplasia : past, present and future. *NIH Public Acces*. 82. 184-199.
- Nickel JC.2008. Inflammation and Benign Prostatic Hyperplasia. *UrolClin North Am*. 35: 109–15.
- Novara G, Galfano A, Berto RB, Ficarra V, Navarrete RV, Artibani W. 2006. Inflammation, apoptosis and BPH: what is the effidence?. *Euro Urol (suppl)*. 5:401-9
- Orihueala E, Pow-Sang M, Motamedi M, Cowan DF, Warren MM. 1996. Mechanism of healing of human prostatic urethra following thermal injury. *Urology*. 48: 600-8.
- Pans A, Albert A, Lapiere CM, Nusgens B. 2001. Biomechanical study of collagen in adult groin hernias. *J Surg Res*. 95:107-13
- Pan H, Vojnits K, Liu TT, Meng F, Yang L, Wang Y, *et al.* 2015. MMP-1 gene expression enhances myoblast migration and engraftment following implanting into mdx/SCID mice. *Cell Adhesion and Migration*, 9:4, 283-92.



Penavic IP. 2001. Endoscopic monitoring of postoperative sinonasal mucosal wound healing. In: Lancu C (ed). Advances in endoscopic surgery. Croatia. In Tech. 419-34.

Parks WC, Wilson CL, Lopez-Boado YS. 2004. Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol* .4(8):617-29.

Pakyari M, Farrokhi A, Maharlooei MK, Ghahary A. 2013. Critical Role of transforming growth factor beta in different phases of wound healing. *Adv Wound care*.2 (5):215-24.

[Penna G](#), [Amuchastegui S](#), [Cossetti C](#), [Aquilano F](#), [Mariani R](#), [Sanvito F](#), *et al*.2006. Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. *J Immunol*.177 : 8504-11.

Periast R, Garzotto M, Kaufman J. 2012. Benign prostatic hyperplasia : A Brief overview of pathogenesis, diagnosis and therapy. Elsevier, 15: 261-64.

Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC. 1997. The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. *J. Cell Biol*;137:1445-57.

[Pilling D](#), [Buckley CD](#), [Salmon M](#), [Gomer RH](#).2003. Inhibition of fibrocyte differentiation by serum amyloid. *P. J.Immunol*.171:5537-46.

Prins GS, Korach KS. 2008. The Role of Estrogens and Estrogen Receptors in Normal Prostate Growth and Disease. *Steroid*. 73:233-44.

Rao KN, Brown MA. 2008. Mast Cells: multifaceted immune cells with diverse roles in health and disease. *Ann N.Y. Acad.Scie* 1143: 83-104.

Rassweiler J, Teber D, Kunt R, Hofmann R. 2006. Complication of Transurethral Resection of The Prostate (TURP)- Incidence, Management, and Prevention. *European Urology*.50:969-80.

Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, *et al*. 2009. Inflammation in benign prostatic hyperplasia: a 282 patients immunohistochemical analysis . *Prostate*.69:1774-80.

Roehborn CG, Mc Connell J. 2007. Etiology, pathophysiology, epidemiology and natural history of benign prostate hyperplasia. In: Wein A.J, Kavoussi L.R, Novick N.C, Partin .A.W, Peters C.A, Editors. *Campbell-Walsh Urology*. 9<sup>th</sup> ed. Philadelphia: Saunders Elsevier; P. 2727-65.

Roehborn CG, Redshaw J, Broghammer JA, Smith TG, Voelzke BB, Erickson BA, *et al*, 2014. Intralesional Injection of Mitomycin C at Transurethral Incision of Bladder Neck Contracture May Offer Limited Benefit: from the TURNS Study Group . *J Urol*.103: 1-2.

- Roeborn CG, Schwinn DA. 2004.  $\alpha_1$ -Adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. *J Urol*.171:1029-35.
- Sae -jung S, Jirattanaphocha K, [SumananontC](#), Wittayapairoj K, Sukhonthamarn K.2015. Interrater Reliability of the Postoperative Epidural Fibrosis Classification: A Histopathologic Study in the Rat Model.[Asian Spine J](#). 9(4): 587–594.
- Schreml S, Szeimies RM, Pranti L, Landthaler M, Babilas P. 2010. Wound Healing in The 21<sup>st</sup> century. *J Am Acad Dermatol*. 63: 866-81
- Schieren G, Gambichler T, Skrygan M, Burkiert B, Altmeyer P, Christian L. 2010. Balance of fibrotic and antifibrotic signaling in nephrogenic systemic fibrosis skin lesions. *American journal of kidney disease*. 55: 1040-49.
- Scholz F, Schulte A, Adamski F, Hundhausen C, Mittag J, Schwarz A, *et al*. 2007. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. *J Invest Dermatol*.127(6):1444–55.
- Shen L, Smith JM, Shen Z, Eriksson M, Sentman C, Wira CR. 2007. Inhibition of human neutrophil degranulation by transforming growth factor  $\beta$ -1. *J Clin Exp Immunol*.149:155-61.
- Shi Y, Massague J. 2003. Mechanism of TGF-  $\beta$  signaling from cell membrane to nucleus. *Cell*.113: 689.
- [Steiner GE](#), [Newman ME](#), [Paikl D](#), [Stix U](#), [Memaran-Dagda N](#), [Lee C](#), *et al*. 2003. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. *Prostate*. 56:171-82
- Sticherling M. 2006. The role of endothelin in connective tissue disease. *Rheumatology*. 45 (Suppl.3): iii8-10.
- Stramer BM, Mori R, Martin P. 2007. The Inflammation –fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. *J. Invest. Dermatol*. 127: 1009-17.
- Stroup SP, Palazzi CK, Kopp RP, Parson JK. 2012. Trends in adverse event of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. *BJU Int*;109:84-7.
- Sugar LM. 2006. Inflammation and prostate cancer. *Can J Urol*.13 (Suppl 1):46-7.
- Tanguay S, Awde M, Brock G, Casey R, Kozak J, Lee J, *et al*.2009. Diagnosis and management of benign prostatic hyperplasia in primary care. *CUAJ*. 3(Suppl): 92- 100.

- Tedgui A, Mallat Z. 2006. Cytokines in atherosclerosis Pathogenic dan regulatory pathways. *Physiol.*86: 515-81.
- Traversa B, Sussman G. 2001. The role of growth factors, cytokines and proteases in wound management. *Primary Intention* .9 : 161-67.
- Verma RP, Hanch C. 2007. Matrix metalloproteinases (MMPs): Chemical–biological functions and (Q)SARs. *Bioorg. Med. Chem.* 15: 2223–68.
- Vuotila T, Ylikontiola L, Sorsa T, Luoto H, Hanemaaijer R, Salo T, *et al.* 2002. The relationship between MMPs and pH in whole saliva of radiated head and neck cancer patients. *J Oral Pathol Med.* 31:329-38.
- Wang W, Huang XR, Li AG, Liu F, Li JH, Truong LD, *et al.* 2005. Signaling mechanism of TGF beta 1 in prevention of renal inflammation: role of Smad 7. *J Am Soc Nephrol.*16:1371-83.
- Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, *et al.* 2011. Cooperative interaction of CTGF and TGF- $\beta$  in animal models of fibrotic disease. *Fibrogenesis and Tissue Repair.* 4:4-15
- Wankell M, Kaesler S, Zhang YQ, Florence C. 2001. The activin binding proteins follistatin and follistatin-related protein are differentially regulated in vitro and during cutaneous wound repair. *J Endocrinol* 171:385-95.
- Westbury CB, Yarnold JR. 2012. Radiation fibrosis-current clinical and Therapeutic Perspectives. *Clinical Oncology.* 24 : 657-72.
- [Wick G](#), [Andersson L](#), [Hala K](#), [Gershwin ME](#), [Selmi CF](#), [Erf GF](#), *et al.* 2006. Avian models with spontaneous autoimmune disease. *Adv Immunol.*92:71-117.
- Wick G, Backovic A, Rabensteiner E, Plank N, Schawenter C, Sgonc R. 2010. The Immunology of fibrosis: innate and adaptive response. *Trends in immunology.* 31: 110-19.
- Wilgus T A, Vodovotz Y, Vittadini E, Clubbs E A, Oberyszyn TM. 2003. Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. *Wound Repair Regen.* 11: 25-34
- Wilson, J. D. (2011). The Critical Role of Androgens in Prostate Development. *Endocrinology and Metabolism Clinics of North America.* 40(3), 577-90.
- Wieczorek E, Reszka E, Jablonowski Z, Jabloska E, Krol MB, *et al.* 2013. *BJU Int.*112:1207-14.
- Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J. 1992. TGF beta signals through a heteromeric protein kinase receptor complex. *Cell.* 71: 1003.

Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. *J Pathol.*214: 199-210.

Zeisber M, Kaluuri R. 2013. Cellular mechanisms of tissue fibrosis. 1: common and organ –specific mechanisms associated with tissue fibrosis. *Am J Physiol Cell Physiol.* 3: 216-25.

Zuhirman, Yanwirasti, Rasyid N.2014. Hubungan Transforming Growth Factor $\beta$  1, Tumor Necrosis Factor- $\alpha$ , Matrix Metalloproteinase-1 dan Fibroblas Growth Factor -2 dengan fibrosis Ureter padaPenderitaBatu Ureter.Disertasi. UniversitasAndalas. Padang

